Ahead of BIO San Diego next month, Shilpa Biologicals has called on emerging biotech companies to rethink how they approach CDMO Selection as investment conditions begin to improve across the biopharma sector. Madhav Bhutada, Director of Shilpa Biologicals, said many innovators developing increasingly sophisticated therapies, including bispecific and trispecific antibodies, continue to depend on a [...] The post Shilpa Biologicals Urges Stronger CDMO Selection Strategy first appeared on World Ph